Brand Reference: Imitrex
| Metric | Verified Benchmark | Source |
|---|---|---|
| Sumatriptan Succinate RxNorm Concept ID | 37418 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $58.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $6.80 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $8.50 / mo | 35 Zero-PHI Verified Patient Logs |
Selectively agonizes meningeal blood-vessel 5-HT1B receptors (reversing neurogenic dural vasodilation) and trigeminal nerve-ending 5-HT1D receptors (halting CGRP and substance P release into the trigeminal nucleus caudalis) to abort acute migraine attacks.
Out-of-pocket price dispersion on Sumatriptan Succinate spans $6.80 to $58.00 per 30-day fill: pharmacy acquisition benchmarks sit near $0.3200/unit, allowing cash buyers bypassing PBM spread pricing to retain $51.20 each month (88% reduction).
With 2.5 hours residence kinetics and 15% oral / 97% subcutaneous autoinjector bioavailability, Sumatriptan Succinate undergoes monoamine oxidase-a oxidative deamination to indole acetic acid analogue and establishes therapeutic activity over 15 min sc / 45–60 min po.
Standard adult regimens span 50 mg PO at aura/headache onset, 100 mg PO (may repeat once >=2h, max 200 mg/24h), 6 mg SC autoinjector. Prescribers screen specifically against coronary artery disease, prinzmetal vasospasm, or prior stroke/tia; hemiplegic or basilar migraine; ergotamine within 24h or mao-a inhibitor within 14d, while community micro-logs most frequently note transient jaw/neck tightness (21% of reports), post-migraine fatigue (19% of reports), warm tingling paresthesia (16% of reports).
Across 35 verified cash-pay logs, Sumatriptan Succinate achieves a 90.30% Worth-It rating with out-of-pocket spend averaging $8.50/mo versus $58.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 50 mg PO at aura/headache onset for Sumatriptan Succinate; monthly out-of-pocket dropped to $5.98 compared with $58.00 retail.
Completed 10 weeks on Sumatriptan Succinate (100 mg PO (may repeat once >=2h, max 200 mg/24h)). Zero notable side effects on steady dosing.
Consistent biomarker response on 6 mg SC autoinjector Sumatriptan Succinate sourced via TeleMed ($7.89/mo cash pay without insurance prior authorization).